Organon (OGN) Deferred Taxes (2020 - 2026)
Organon (OGN) posted quarterly Deferred Taxes of $3.0 million for Q1 2026, up 117.65% year-over-year from $1.4 million in Q1 2025, and down 90.0% on a QoQ basis from $30.0 million in Q4 2025.
Organon (OGN) Deferred Taxes (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Deferred Taxes for 7 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes rose 117.65% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $83.0 million (up 145.6% YoY), while the FY2025 annual figure was $63.0 million, up 139.37% from the prior year.
- Deferred Taxes came in at $3.0 million for Q1 2026 at Organon, down from $30.0 million in the prior quarter.
- The five-year high for Deferred Taxes was $40.0 million in Q3 2025, with the low at -$489.0 million in Q4 2023.
- Average Deferred Taxes over 5 years is -$36.3 million, with a median of $3.0 million recorded in 2023.
- The largest YoY upside for Deferred Taxes was 400.0% in 2024 against a maximum downside of 2550.0% in 2024.
- Year by year, Deferred Taxes stood at -$20.0 million in 2022, then slumped by 2345.0% to -$489.0 million in 2023, then jumped by 102.04% to $10.0 million in 2024, then soared by 200.0% to $30.0 million in 2025, then tumbled by 90.0% to $3.0 million in 2026.
- According to Business Quant data, Deferred Taxes over the past three periods registered $3.0 million, $30.0 million, and $40.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 1.48 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 159.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 137.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 30.00 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | -17.00 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | -196.00 Mn |
| Jun 30, 2024 | 21.00 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | -489.00 Mn |
| Sep 30, 2023 | 8.00 Mn |
| Jun 30, 2023 | -7.00 Mn |
| Mar 31, 2023 | 3.00 Mn |
| Dec 31, 2022 | -20.00 Mn |
| Sep 30, 2022 | -9.00 Mn |
| Jun 30, 2022 | -5.00 Mn |
| Mar 31, 2022 | -4.00 Mn |
| Dec 31, 2021 | -76.00 Mn |
| Sep 30, 2021 | -41.00 Mn |
| Jun 30, 2021 | -146.00 Mn |